Category English

EU-US Comparison & Guide On Copyright Link Liability – An Update

Ed Klaris and Alexia Bedat write: An update to our article reviewing US and European law/recent developments in link liability in both the copyright and defamation contexts and providing a checklist of questions an attorney (or editor) ought to ask before deciding, prepublication, whether a proposed link may lead to liability in the US and/or the EU. Updates include the recent Goldman v. Breitbart decision in which a Federal Judge concluded that embedding a Tweet can be copyright infringement.

Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition

The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled.

What You Can Learn From The Licensing Execs At The LESI Annual Conference 2018

“Strong IP Drives the Bottom Line”: Licensing executives, technology transfer officers and attorneys from all over the world met under this theme at the annual conference of the Licensing Executives Society International (LESI) in San Diego from April 30 to May 1, 2018.

Each year, the LESI annual conference brings together the strategists, pioneers and deal makers of the world to exchange about the hot topics in licensing, technology transfer and the business of IP. Bastian July of GoodIP reports on what you can learn from the keynote speeches and workshops he attended.

US State-By-State Analysis Shows Benefits Of Funding Global Health Research

In the current atmosphere in the United States of funding cuts for global health threats like malaria and HIV/AIDS by the Trump Administration, a new state-by-state analysis claims to show its profound implications for research and jobs across the country.

Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim

BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said.

New Guidelines For Tech Companies To Be Transparent, Accountable On Censoring User Content

Facebook, Google and other social media companies today were urged by groups such as the Electronic Frontier Foundation to "publicly report how many user posts they take down, provide users with detailed explanations about takedowns, and implement appeals policies to boost accountability." The groups released a set of guidelines to address censorship.

Civil Society Key In TRIPS Flexibility Implementation

When the agreement on intellectual property was adopted by the World Trade Organization, a number of flexibilities were included in the text, mainly to give developing countries policy space to implement the agreement with development considerations. However, some countries through lack of awareness or economic pressure have not used those flexibilities fully, and found themselves facing difficulties addressing their public health needs, which some associate with this failure to use the flexibilities. Civil society has engaged in notable efforts to counter pressure and raise policymakers' awareness for a wider access to medicines.

Brazil’s Federal Court Reviews Medicines Mailbox Patents

This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is.